Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China -- -- SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023, with commercial value driven via bilateral supply agreements expected beginning in 2023 --

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

Alpha Metallurgical Resources

Atkore International Group

EOG Resources

Open Lending Corp

Lam Research

Vector Group

With 2022 in the rearview mirror, it's time to hunt for solid, undervalued long-term stocks to buy. First, it's essential to define what is meant by long-term.

The 7 Most Undervalued Long-Term Stocks to Buy in January

Preliminary full year 2022 HEPLISAV-B® vaccine Net Product Revenue of approximately $126 million, representing 104% growth compared to 2021 Preliminary full year CpG 1018® adjuvant Net Product Revenue of approximately $588 million Maintained strong financial position with year-end cash and investments of approximately $624 million Phase 1 shingles trial results demonstrate favorable tolerability with similar vaccine response rates in CpG 1018 adjuvanted arms versus comparator vaccine EMERYVILLE, Calif. , Jan. 9, 2023 /PRNewswire/ --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced preliminary, unaudited financial highlights for the fourth quarter and full year ending December 31, 2022 and Phase 1 shingles topline results.

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results

Ameriprise Financial

Alphabet

Playa Hotels & Resorts

Hostess Brands

Copa Hlds

In 2022, the S&P 500 had its worst year since 2008, with a total return of -18.11%, nearly 47 percentage points worse than in 2021. But it could have been much worse.

7 Cheap Stocks That Wall Street Analysts Still Love

Valneva SE

Saint- Herb lain (France ) , December 30 , 202 2 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.

Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

Cal-Maine Foods

Cavco Industries

Warrior Met Coal

Kulicke & Soffa Industries

Marcus & Millichap

Encore Wire

One of the more fun assignments at InvestorPlace is selecting the top small-cap stock picks for 2023. In this case, I've been chosen to provide readers with seven options for next year.

Our 7 Top Small-Cap Stock Picks for 2023

-- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo -- -- Results indicate that vaccination with SCB-2019 can potentially help control the spread of SARS-CoV-2 within communities through the reduction of transmission to household contacts and through previously demonstrated efficacy against SARS-CoV-2 --

Clover's Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

EMERYVILLE, Calif. , Nov. 9, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, and Kelly MacDonald , Chief Financial Officer, will participate in two upcoming investor conferences: Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day Fireside chat: Monday, November 14, 2022, 10:10 a.m.

Dynavax to Present at Two Upcoming Investor Conferences

Dynavax Technologies (DVAX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Dynavax Technologies (DVAX) Stock

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?

When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

Dynavax Technologies (DVAX) Recently Broke Out Above the 200-Day Moving Average

The consensus price target hints at a 154.4% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 154% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?

Vaccine play Dynavax Technologies once again delivered stellar quarterly results after the bell on Thursday. Despite this, the stock continues to get a muted reaction from the investment community.

Dynavax Technologies: Stellar Results, But Little Respect

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 30.30% and 11.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Beats Q3 Earnings and Revenue Estimates

Dynavax Technologies Corporation (NASDAQ:DVAX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Donn Casale - SVP, Commercial Rob Janssen - CMO Kelly MacDonald - CFO Conference Call Participants Roy Buchanan - JMP Securities Matthew Phipps - William Blair Ernesto Rodriguez-Dumont - Cowen Operator Good day ladies and gentlemen and welcome to the Dynavax Technologies' Third Quarter 2022 Financial Results. As a reminder, this conference call is being recorded.

Dynavax Technologies Corporation (DVAX) Q3 2022 Earnings Call Transcript

Q3 2022 total revenue of $167.7 million, up 55% from $108.3 million for Q3 2021 HEPLISAV-B ®  vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 CpG 1018 ® adjuvant net product revenue of $126.3 million, up 50% from $84.3 million for Q3 2021 Reiterates guidance for full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million  On track for a second consecutive year of profitability Conference call today at 4:30 p.m. ET/1:30 p.m.

Dynavax Reports Third Quarter 2022 Financial Results

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Dynavax Technologies (DVAX) Recently Broke Out Above the 50-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Dynavax Technologies (DVAX) Crossed Above the 20-Day Moving Average: What That Means for Investors

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 210.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Dynavax Technologies (DVAX) Have the Potential to Rally 210% as Wall Street Analysts Expect?

EMERYVILLE, Calif. , Oct. 20, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter financial results on Thursday, November 3, 2022, after the U.S. financial markets close.

Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022

Should Value Investors Buy Dynavax Technologies (DVAX) Stock?

EMERYVILLE, Calif. , Oct. 14, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C.

Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference

Oxford Industries

Preferred Bank

If under-the-radar small-cap stocks are your jam, I've got three selections from the S&P SmallCap 600 that might be right up your alley. The small-cap index is down 20.3% year to date.

3 Under-the-Radar Small-Cap Stocks With 100% Upside Potential

-- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clover's lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4 2022 -- -- New data demonstrating superiority as a heterologous booster compared to inactivated vaccine, robust neutralization of globally dominant Omicron BA.5 strain, and 84% reduction in transmission of SARS-CoV-2 infection to household contacts --

Clover Provides Update on 2022 Corporate Milestones

Agenus

CureVac B.V

Immunocore Holdings

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

News for Dynavax Technologies Stock (DVAX)